Neuroscience

Human brain
#Cell and gene therapy #Cell therapy #Gene therapy #Neurodegenerative disorders #Neuroscience

Five cell and gene therapy advances in neurodegeneration

Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus… Read More

#Exclusive Content

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Older adult receiving vaccine
#Dementia #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Shingles #University of Oxford

New shingles vaccine found to reduce risk of dementia

New evidence indicates that a new shingles vaccine is more protective against dementia compared to the previous shingles vaccine, which was also reported to reduce dementia rates. It is also more protective than vaccines against other infections. A study of more… Read More

#News

Cancer research
#Amyotrophic lateral sclerosis (ALS) #Neurology #Neuroscience #Phase II trial #TikoMed

‘Encouraging’ results for potential disease-modifying ALS drug

New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS). The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics… Read More

#Editor's Choice #News

Human brain
#Funding #Lario Therapeutics #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Lario Therapeutics awarded $6m for Parkinson’s drug research

Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of… Read More

#News

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment… Read More

#News #Regulatory

#Funding #Mission Therapeutics #Neurodegenerative disorders #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Mission awarded $5.2m for disease-modifying Parkinson’s treatment

Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30 inhibitor, which is designed to protect dopamine-producing… Read More

#Business & Investment #Editor's Choice #News

Demyelination of neuron
#Amyotrophic lateral sclerosis (ALS) #Neurodegenerative disorders #Neuroscience #Partnership

New Scandinavian ALS drug research collaboration

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS). TikoMed has previously completed and reported on two successful Phase IIa clinical studies in ALS, one at… Read More

#News

Brain physiology
#Neuroscience #Newron Pharmaceuticals #Schizophrenia

Drug’s unique mechanism of action targets schizophrenia abnormalities

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic… Read More

#Editor's Choice #News

MRI of the brain
#AviadoBio #Dementia #Gene therapy #Neurodegenerative disorders #Phase II trial

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

DDW Highlights podcast expands to include vodcast 

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week has seen… Read More

#News

ALS concept
#Amyotrophic lateral sclerosis (ALS) #Biomarkers #Drug discovery #Neuroscience #Partnership

How a new partnership aims to tackle ALS

DDW Editor Reece Armstrong speaks to Alessio Travaglia, PhD, Director, Translational Science, Neuroscience, Foundation for the National Institutes of Health (FNIH) about challenges in treating amyotrophic lateral sclerosis (ALS) and why a new public-private partnership launched by the FNIH is hoping to advance new drugs and diagnostics for the disease.   RA:… Read More

#Exclusive Content

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA approves second anti-amyloid beta antibody for Alzheimer’s

Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients with mild cognitive impairment… Read More

#News #Regulatory #Trending News

The Hospital for Sick Children (SickKids) in Toronto, Canada
#Gene therapy #Genetics / genomics #Neurodegenerative disorders #Rare disease

Gene therapy halts progression of rare genetic condition

The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More

#News #Trending News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

New DDW Highlights podcast: 1 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It is also available to watch as a vodcast:  This week… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

This week in drug discovery (24-28 June) 

News round-up for 24-28 June by DDW Senior Digital Content Editor Diana Spencer. This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as… Read More

#News